Federal Register / Vol. 63, No. 111 /Wednesday, June 10, 1998 / Notices 31781

D. The Office of Information

Technology Development is responsible

for:

1. Leading Departmental efforts to

develop and utilize electronic methods

for conducting business among all

components of the Department, all

agencies of the Federal government, and

all parties involved in accomplishing

Departmental program objectives

(including State Governments,

contractors, grantees, other service

providers, and the general public). This

includes provision of existing

documents in electronic format on the

Internet in support of electronic

dissemination to the public.

2. Manage and support the HHS

Internet Information Management

Council, as the focal point for Internet

information management and

dissemination issues and Departmental

policies to guide HHS’s expanding

Internet presence.

3. Identify key emerging, enabling

technologies, especially Internet and

database innovations, and coordinate,

manage, or direct pilot projects in these

areas to establish proof of concept,

confirm return on investment, or

implement initial production

implementations in support of agency

IT business requirement.

4. Supporting implementation of a

general purpose, standards-based IT

architecture, promoting and

coordinating implementation of data

standards for information integration

across application systems, utilizing

distributed computing environments

consisting of data communications

networks, data base management

systems, and information processing

platforms.

5. Assisting ASMB/OS managers to

implement and maintain database

applications to increase the value and

quality of their services and to control

risks associated with systems

integration, technological obsolescence,

software development, and migration to

standards-based technologies, especially

for systems automating common

administrative and management service.

6. Representing the Department

through participation on interagency

and Departmental work groups and task

forces.

Dated: May 26, 1998.

John J. Callahan,

Assistant Secretary for Management and

Budget.

[FR Doc. 98–15387 Filed 6–9–98; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Announcement 98058]

National Institute for Occupational

Safety and Health: Cooperative

Agreement To Identify the Incidence of

Occupational Asthma; Notice of

Availability of Funds for Fiscal Year

1998

Introduction

The Centers for Disease Control and

Prevention (CDC), the Nation’s

prevention agency, announces the

availability of funds for fiscal year (FY)

1998 for a cooperative agreement

program to identify incident cases of

occupational asthma in a defined

population, in order to calculate the

incidence of occupational asthma for

the defined population and by specific

industries and occupations within that

population.

CDC is committed to achieving the

health promotion and disease

prevention objectives of Healthy People

2000, a national activity to reduce

morbidity and mortality and improve

the quality of life. This announcement

is related to the priority area of

Occupational Safety and Health. (For

ordering a copy of Healthy People 2000,

see the section WHERE TO OBTAIN

ADDITIONAL INFORMATION.)

Authority

This program is authorized under

Sections 20(a) and 22(e)(7) of the

Occupational Safety and Health Act of

1970 [29 U.S.C. 669(a) and 671(e)(7)].

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke-free

workplace and promote the non-use of

all tobacco products, and Pub. L. 103–

227, the Pro-Children Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day care, health care,

and early childhood development

services are provided to children.

Eligible Applicants

Applications may be submitted by

public and private, nonprofit and forprofit organizations and governments

and their agencies. Thus, universities,

colleges, research institutions, hospitals,

other public and private organizations,

State and local governments or their

bona fide agents, federally recognized

Indian tribal governments, Indian tribes

or Indian tribal organizations, and

small, minority and/or woman-owned

businesses are eligible to apply.

Note: Pub. L. 104–65, dated December 19,

1995, prohibits an organization described in

section 501(c)(4) of the IRS Code of 1986, that

engages in lobbying activities shall not be

eligible for the receipt of Federal funds

constituting an award, grant, contract, loan,

or any other form of funding.

Availability of Funds

Approximately $200,000 is available

in FY 1998 to fund one or two awards.

If one award is made, the award will be

funded up to $200,000. If two awards

are funded, the average award will be

$100,000. The amount of funding

available may vary and is subject to

change. This award is expected to begin

on or about September 30, 1998. The

award will be made for a 12-month

budget period within a project period

not to exceed 3 years. Continuation

awards within the project period will be

made on the basis of satisfactory

progress and availability of funds.

Use of Funds

Restrictions on Lobbying

Applicants should be aware of

restrictions on the use of HHS funds for

lobbying of Federal or State legislative

bodies. Under the provisions of 31

U.S.C. Section 1352 (which has been in

effect since December 23, 1989),

recipients (and their subtier contractors)

are prohibited from using appropriated

Federal funds (other than profits from a

Federal contract) for lobbying Congress

or any Federal agency in connection

with the award of a particular contract,

grant, cooperative agreement, or loan.

This includes grants/cooperative

agreements that, in whole or in part,

involve conferences for which federal

funds cannot be used directly or

indirectly to encourage participants to

lobby or to instruct participants on how

to lobby.

In addition, the current HHS

Appropriations Act expressly prohibits

the use of appropriated funds for

indirect or ‘‘grass roots’’ lobbying efforts

that are designed to support or defeat

legislation pending before state

legislatures. Section 503 of the law

provides as follows:

Sec. 503(a) No part of any appropriation

contained in this Act shall be used, other

than for normal and recognized executivelegislative relationships, for publicity or

propaganda purposes, for the preparation,

distribution, or use of any kit, pamphlet,

booklet, publication, radio, television, or

video presentation designed to support or

defeat legislation pending before the

Congress, or any State legislature, except in

presentation to the Congress or any State

legislative body itself.
31782 Federal Register / Vol. 63, No. 111 /Wednesday, June 10, 1998 / Notices

(b) No part of any appropriation

contained in this Act shall be used to

pay the salary or expenses of any grant

or contract recipient, or agent acting for

such recipient, related to any activity

designed to influence legislation or

appropriations pending before the

Congress or any State legislature.

Department of Labor, Health and

Human Services, and Education, and

Related Agencies Appropriations Act,

1997, as enacted by the Omnibus

Consolidated Appropriations Act, 1997,

Division A, Title I, Section 101(e), Pub.

L. No. 104–208 (September 30, 1996).

Background

A useful operational definition of

occupational asthma (OA) was

developed as part of the NIOSHsponsored Sentinel Event Notification

System for Occupational Risks

(SENSOR). CDC Occupational disease

surveillance: occupational asthma.

MMWR 1990; 39:119–123). For the

purposes of this announcement, OA is

considered to encompass many different

types of cases in which asthma is

associated with occupational exposures.

OA is intended to include asthma cases

whose onset is attributed to workplace

exposures/conditions, preexisting

asthma cases whose symptoms have

been quiescent but are initiated anew by

workplace exposures/conditions, and

ongoing cases of preexisting asthma

whose illness is made significantly

worse by workplace exposures/

conditions or for whom an increase in

treatment to maintain clinical stability

is due to workplace exposures/

conditions. Also, there are a variety of

workplace exposures/conditions that

can initiate or exacerbate asthma: (a)

sensitizing agents (e.g., small or large

molecular weight compounds); (b) brief,

high-level irritant exposures (e.g., as

with reactive airways dysfunction

syndrome, or RADS); (c) repeated lowlevel irritant exposures; (d) bronchoconstricting pharmacologic agents (e.g.,

as with byssinosis or polymer fume

fever); (e) physical stimuli (e.g., exercise

or exposure to cold).

Occupational asthma is the most

common lung disease seen in

occupational health clinics in the

United States based on data from the

Association of Occupational and

Environmental Clinics for 1991–1996.

Accurate estimates of incidence are

needed to evaluate the medical, social,

and economic impact of this disease.

Unfortunately, incidence estimates are

few and vary widely, ranging from 5 to

710 cases/106/year. NIOSH has funded

surveillance for OA since 1987 through

the SENSOR program. Estimates of

incidence based on SENSOR activities

range from a low of 5 cases/106/year in

Massachusetts during 1988–1992 to a

high of 44 cases/106/year in Michigan

during 1993. However, SENSOR

activities have the primary goal of

identifying and improving dangerous

worksites rather than providing a

complete count of cases. Consequently,

incidence figures based on SENSOR

data underestimate the actual number of

diagnosed cases.

The episodic nature of asthma

symptoms makes it difficult to obtain

objective evidence of work-relatedness.

The difficulty of this task and limits on

patient-contact time discourage the

routine investigation of workrelatedness by many health care

providers. In fact, two recent studies

report that over 80% of providers fail to

explore work-relatedness of adult

asthma. This observation has at least

two implications for measuring the

frequency of OA. First, enhancement of

existing surveillance activities to

identify all diagnosed OA would still

exclude the cases who have gone

unnoticed because their health care

providers did not explore the workrelatedness of asthma. Second, studies

that attempt to count incident OA cases

must include evaluation of workrelatedness of symptoms for all cases of

asthma in adults, and not rely on health

care providers to explore this possible

association.

The fact that OA can be initiated by

over 200 agents used in hundreds of

different processes argues for a

population-based rather than industryspecific approach to measuring

incidence. In the absence of

nationalized health care in the United

States, health maintenance

organizations (HMOs) provide unique

opportunities for population-based

studies of asthma. The feasibility of

using HMO data to measure OA

incidence was demonstrated in a recent

study. The investigators estimated the

incidence of asthma attributable to

occupation was 710 cases/106/year, a

figure over 16 times greater than the

highest SENSOR estimate.

An indirect estimate of OA incidence

is derived by knowing both the

incidence of adult-onset asthma and the

proportion of cases that are workrelated. The incidence of new onset

asthma among adults during the years

from 1971–1974 to 1982–1984 was

estimated at 2100 cases/106/year by the

NHANES–1 Epidemiologic Follow-up

Survey. The proportion of incident

cases due to occupation can be

estimated by using the same proportion

estimated for prevalent asthma cases,

which ranges from 0.03 to 0.20 based on

studies in the United States. The

product of this range of proportions and

the asthma incidence from the NHANES

study yields estimates of OA incidence

63 to 420 cases/106/year. Even the low

estimate of 63 cases/106/year exceeds

the highest estimate of 44 cases/106/year

reported by the SENSOR program.

These indirect estimates and the

estimate of 710 cases/106/year from the

HMO study suggest that OA is a more

common condition in the United States

than previously thought.

Additional research is needed to

elaborate the incidence of occupational

asthma and the industries and

occupations at highest risk. By having

accurate estimates of incidence, it will

be possible to make appropriate

allocation of resources to address this

problem. Knowledge of the industries

and occupations at highest risk will

assist future planning for focused

studies or preventive interventions.

Purpose

The purpose of this program is to: 1.

evaluate the work-relatedness of

incident asthma cases in a defined

population (e.g., an HMO) during a

minimum 12-month period (in order to

account for seasonal variation of

incidence), and calculate (a) the

incidence of occupational asthma for

the defined population; (b) the

incidence of occupational asthma for

specific industries and/or occupations

in the defined population; and (c) the

proportion of all incident asthma cases

that are associated with workplace

exposures; and 2. encourage the use of

population-based data to investigate the

impact of occupational diseases.

Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for activities under

A. (Recipient Activities), and CDC/

NIOSH will be responsible for the

activities listed under B. (CDC/NIOSH

Activities).

A. Recipient Activities

1. Develop and implement a research

protocol.

2. Develop, field test, and revise data

collection instruments.

3. Analyze data and interpret

findings.

4. Disseminate research results to the

scientific community.

5. Collaborate with CDC/NIOSH on

these activities, and the activities listed

below.

6. Meet annually at CDC/NIOSH to

coordinate planned efforts and review

progress.
Federal Register / Vol. 63, No. 111 /Wednesday, June 10, 1998 / Notices 31783

B. CDC/NIOSH Activities

1. Provide scientific, epidemiologic,

engineering, environmental, industrial

hygiene, and clinical technical

assistance.

2. Collaborate on the development of

the research protocol(s).

3. Provide technical assistance on the

development and evaluation of the data

collection instruments.

4. Collaborate with awardee(s) on data

analysis, and interpretation of findings.

5. Provide technical assistance to

awardees (if more than one award is

made) to ensure that the methods used

are similar enough so that data can be

meaningfully combined.

6. Provide assistance for the

dissemination of information resulting

from this project.

7. Facilitate an annual meeting

between awardee(s) and CDC/NIOSH to

coordinate planned efforts and review

progress.

Technical Reporting Requirements

An original and two copies of a

progress report are required semiannually. Timelines for the semi-annual

reports will be established at the time of

award. Final financial status and

performance reports are required no

later than 90 days after the end of the

project period. All reports are submitted

to the Grants Management Branch,

Procurement and Grants Office, CDC.

The semi-annual progress report

should include:

A. A brief program description.

B. A listing of program goals and

objectives accompanied by a

comparison of the actual

accomplishments related to the goals

and objectives established for the

period.

C. If established goals and objectives

to be accomplished were delayed,

describe both the reason for the

deviation and anticipated corrective

action or deletion of the activity from

the project.

D. Other pertinent information,

including the status of completeness,

timeliness and quality of data.

Application Content

The entire application, including

appendices, should not exceed 40 pages

and the Proposal Narrative section

contained therein should not exceed 25

pages. Pages should be clearly

numbered and a complete index to the

application and any appendices

included. The original and each copy of

the application must be submitted

unstapled and unbound. All materials

must be typewritten, double-spaced,

with unreduced type (font size 12 point)

on 81⁄2′′ by 11′′ paper, with at least 1′′

margins, headers, and footers, and

printed on one side only. Do not include

any spiral or bound materials or

pamphlets.

A. Title Page

The heading should include the title

of grant program, project title,

organization, name and address, project

director’s name address and telephone

number.

B. Abstract

A one page, singled-spaced, typed

abstract must be submitted with the

application. The heading should

include the title of grant program,

project title, organization, name and

address, project director and telephone

number. This abstract should include a

work plan identifying activities to be

developed, activities to be completed,

and a time-line for completion of these

activities.

C. Proposal Narrative

The narrative of each application

must:

1. Briefly state the applicant’s

understanding of the need or problem to

be addressed, the purpose, and goals

over the 3 year period of the cooperative

agreement.

2. Describe in detail the objectives

and the methods to be used to achieve

the objectives of the project. The

objectives should be specific, timephased, measurable, and achievable

during each budget period. The

objectives should directly relate to the

program goals. Identify the steps to be

taken in planning and implementing the

objectives and the responsibilities of the

applicant for carrying out the steps.

3. Provide the name, qualifications,

and proposed time allocation of the

Project Director who will be responsible

for administering the project. Describe

staff, experience, facilities, equipment

available for performance of this project,

and other resources that define the

applicant’s capacity or potential to

accomplish the requirements stated

above. List the names (if known),

qualifications, and time allocations of

the existing professional staff to be

assigned to (or recruited for) this

project, the support staff available for

performance of this project, and the

available facilities including space.

4. Document the applicant’s expertise,

and extent of experience in the areas of

asthma, occupational lung diseases, and

population-based studies.

5. Provide letters of support or other

documentation demonstrating

collaboration where collaboration is

necessary for the conduct of the

investigation.

6. Human Subjects: State whether or

not Humans are subjects in this

proposal. (See Human Subjects in the

Evaluation Criteria and Other

Requirements sections.)

7. Inclusion of women, ethnic, and

racial groups:

Describe how the CDC policy

requirements will be met regarding the

inclusion of women, ethnic, and racial

groups in the proposed research. (See

Women, Racial and Ethnic Minorities in

the Evaluation Criteria and Other

Requirements sections.)

D. Budget

Provide a detailed budget which

indicates anticipated costs for

personnel, equipment, travel,

communications, supplies, postage, and

the sources of funds to meet these

needs. The applicant should be precise

about the program purpose of each

budget item. For contracts described

within the application budget,

applicants should name the contractor,

if known; describe the services to be

performed; and provide an itemized

breakdown and justification for the

estimated costs of the contract; the

kinds of organizations or parties to be

selected; the period of performance; and

the method of selection. Place the

budget narrative pages showing, in

detail, how funds in each object class

will be spent, directly behind form

424A. Do not put these pages in the

body of the application. CDC may not

approve or fund all proposed activities.

Evaluation Criteria

The application will be reviewed and

evaluated according to the following

criteria:

A. Understanding of the Problem (10%)

Responsiveness to the objectives of

the cooperative agreement including (1)

the applicant’s understanding of the

general objectives of the proposed

cooperative agreement, and (2)

relevance of the proposal to the

objectives.

B. Program Personnel (20%)

1. Applicant’s technical experience

and understanding (e.g., in the areas of

asthma, occupational lung diseases, and

population-based studies).

2. Qualifications and time allocation

of the professional staff to be assigned

to this project.

3. Extent to which the management

staff and their working partners are

clearly described.
31784 Federal Register / Vol. 63, No. 111 /Wednesday, June 10, 1998 / Notices

C. Goals, Objectives, and Study Design

(Total 60%)

1. The extent to which the proposed

goals and objectives are clearly stated

and measurable. Adequacy of the study

design and methodology for

accomplishing the stated goals and

objectives. A description of the study

methodology, data to be collected, and

the respective responsibilities of the

applicant for carrying out these steps.

The degree to which efficient and

innovative approaches are proposed to

address the problems. Issues of specific

concern to this project include the

adequacy of the applicant’s (a) evidence

of access to an appropriate study

population; (b) description of the study

population, including the occupation/

industry mix; (c) operational definitions

for asthma and occupational asthma; (d)

methods for identifying incident asthma

cases and assessing work-relatedness of

asthma. The extent to which the

applicant’s plans and schedule

proposed for accomplishing the

activities to be carried out in this project

are clearly stated, are realistic given the

length of the funding period, and can be

achieved within the proposed budget.

2. The degree to which the applicant

has met the CDC policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed project. This includes: (a) The

proposed plan for the inclusion of both

sexes and racial and ethnic minority

populations for appropriate

representation; (b) The proposed

justification when representation is

limited or absent; (c) A statement as to

whether the design of the study is

adequate to measure differences when

warranted; and (d) A statement as to

whether the plan for recruitment and

outreach for study participants includes

the process of establishing partnerships

with community(ies) and recognition of

mutual benefits.

D. Facilities and Resources (10%)

The adequacy of the applicant’s

facilities, equipment, and other

resources available for performance of

this project.

E. Human Subjects (Not scored)

Whether or not exempt from the

Department of Health and Human

Services (DHHS) regulations, are

procedures adequate for the protection

of human subjects? Recommendations

on the adequacy of protections include:

(1) protections appear adequate, and

there are no comments to make or

concerns to raise, (2) protections appear

adequate, but there are comments

regarding the protocol, (3) protections

appear inadequate and the Objective

Review Group has concerns related to

human subjects or (4) disapproval of the

application is recommended because

the research risks are sufficiently

serious and protection against the risks

are inadequate as to make the entire

application unacceptable.

F. Budget Justification (Not Scored)

The budget will be evaluated to the

extent that it is reasonable, clearly

justified, and consistent with the

intended use of funds.

Executive Order 12372 Review

The applicant is not subject to review

under Executive Order 12372 Review.

Public Health System Reporting

Requirements

The applicant is not subject to review

under the Public Health System

Reporting Requirements.

Catalog of Federal Domestic Assistance

Number

The Catalog of Federal Domestic

Assistance number is 93.957.

Other Requirements

Paperwork Reduction Act

Projects that involve the collection of

information from ten or more

individuals and funded by this

cooperative agreement will be subject to

review and approval by the Office of

Management and Budget (OMB) under

the Paperwork Reduction Act.

Human Subjects

If the proposed project involves

research on human subjects, the

applicant must comply with the DHHS

Regulations, 45 CFR Part 46, regarding

the protection of human subjects.

Assurance must be provided to

demonstrate the project will be subject

to initial and continuing review by an

appropriate institutional review

committee. The applicant will be

responsible for providing assurance in

accordance with the appropriate

guidelines and form provided in the

application kit.

In addition to other applicable

committees, Indian Health Service (IHS)

institutional review committees also

must review the project if any

component of IHS will be involved or

will support the research. If any

American Indian community is

involved, its tribal government must

also approve that portion of the project

applicable to it.

Confidentiality

All personal identifying information

obtained in connection with the

delivery of services provided to any

person in any program carried out under

this cooperative agreement cannot be

disclosed unless required by a law of a

State or political subdivision or unless

such a person provides written,

voluntary informed consent.

A. Nonpersonal identifying, unlinked

information, which preserves the

individual’s anonymity, derived from

any such program may be disclosed

without consent:

1. In summary, statistical, or other

similar form, or

2. For clinical or research purposes.

B. Personal identifying information:

Recipients of CDC funds who must

obtain and retain personally identifying

information as part of their CDCapproved work plan must:

1. Maintain the physical security of

such records and information at all

times;

2. Have procedures in place and staff

trained to prevent unauthorized

disclosure of client-identifying

information;

3. Obtain informed client consent by

explaining the risks of disclosure and

the recipient’s policies and procedures

for preventing unauthorized disclosure;

4. Provide written assurance to this

effect including copies of relevant

policies; and

5. Obtain assurances of confidentiality

by agencies to which referrals are made.

Assurance of compliance with these

and other processes to protect the

confidentiality of information will be

required of all recipients. A DHHS

certificate of confidentiality may be

required for some projects.

Women, Racial and Ethnic Minorities

It is the policy of the Centers for

Disease Control and Prevention (CDC)

and the Agency for Toxic Substances

and Disease Registry (ATSDR) to ensure

that individuals of both sexes and the

various racial and ethnic groups will be

included in CDC/ATSDR-supported

research projects involving human

subjects, whenever feasible and

appropriate. Racial and ethnic groups

are those defined in OMB Directive No.

15 and include American Indian, Alaska

Native, Asian, Black or African

American, Hispanic or Latino, and

Native Hawaiian or other Pacific

Islander. Applicants shall ensure that

women, racial and ethnic minority

populations are appropriately

represented in applications for research

involving human subjects. Where clear

and compelling rationales exist that

inclusion is inappropriate or not

feasible, this situation must be

explained as part of the application.

This policy does not apply to research
Federal Register / Vol. 63, No. 111 /Wednesday, June 10, 1998 / Notices 31785

studies when the investigator cannot

control the race, ethnicity and/or sex of

subjects. Further guidance to this policy

is contained in the Federal Register,

Vol. 60, No. 179, pages 47947–47951,

and dated Friday, September 15, 1995.

Application Submission and Deadlines

A. Preapplication Letter of Intent

Although not a prerequisite of

application, a non-binding letter of

intent-to-apply is requested from

potential applicants. The letter should

be submitted to Victoria F. Sepe, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, CDC at the address listed

in this section. It should be postmarked

no later than July 2, 1998. The letter

should identify program announcement

number 98058, and name of the

principal investigator. The letter of

intent does not influence review or

funding decisions, but it will enable

CDC to plan the review more efficiently

and will ensure that each applicant

receives timely and relevant information

prior to application submission.

B. Application

The original and two copies of the

application PHS Form 5161–1 (Revised

7/92, OMB Number 0937–0189) must be

submitted to Victoria Sepe, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE, Room 321,

Atlanta, GA 30305, on or before July 31,

1998.

1. Deadline: Applications will be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date, or

(b) Sent on or before the deadline date

and received in time for submission to

the objective review group. (The

applicants must request a legibly dated

U.S. Postal Service postmark or obtain

a receipt from a commercial carrier or

the U.S. Postal Service. Private metered

postmarks will not be acceptable as

proof of timely mailing.)

2. Late Applicants: Applications that

do not meet the criteria in 1.(a) or 1.(b)

above are considered late applications.

Late applications will not be considered

in the current competition and will be

returned to the applicants.

Where To Obtain Additional

Information

To receive additional written

information call 1–888–GRANTS4. You

will be asked to leave your name,

address, and phone number and will

need to refer to NIOSH Announcement

98058. You will receive a complete

program description, information on

application procedures, and application

forms. CDC will not send application

kits by facsimile or express mail.

PLEASE REFER TO NIOSH

ANNOUNCEMENT NUMBER 98058

WHEN REQUESTING INFORMATION

AND SUBMITTING AN APPLICATION.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from

Victoria Sepe, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), Mailstop E–13, Room 321, 255

East Paces Ferry Road, NE., Atlanta, GA

30305, telephone (404) 842–6804,

Internet: vxw1@cdc.gov.

Programmatic technical assistance

may be obtained from Paul K.

Henneberger, MPH, ScD, Research

Epidemiologist, Division of Respiratory

Disease Studies, National Institute for

Occupational Safety and Health, Center

for Disease Control and Prevention

(CDC), Mailstop 234, 1095 Willowdale

Road, Morgantown, WV 26505,

telephone 304–285–6161, or Internet:

pkh0@.cdc.gov.

This and other CDC announcements

are available through the CDC homepage

on the Internet. The address for the CDC

homepage is: http://www.cdc.gov.

Potential applicants may obtain a

copy of Healthy People 2000 (Full

Report, Stock No. 017–001–00474–0) or

Healthy People 2000 (Summary Report,

Stock No. 017–001–00473–1) through

the Superintendent of Documents,

Government Printing Office,

Washington, DC 20402–9325, telephone

(202) 512–1800.

The National Occupational Research

Agenda

Copies of this publication may be

obtained from The National Institute of

Occupational Safety and Health,

Publications Office, 4676 Columbia

Parkway, Cincinnati, OH 45226–1998 or

phone 1–800–356–4674, and is available

through the NIOSH Home Page; ‘‘http:/

www.cdc.gov/niosh/nora.html’’.

Dated: June 2, 1998.

Diane D. Porter,

Acting Director, National Institute For

Occupational Safety and Health Centers For

Disease Control and Prevention (CDC).

[FR Doc. 98–15359 Filed 6–9–98; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Statement of Organization, Functions,

and Delegations of Authority

Part C (Centers for Disease Control

and Prevention) of the Statement of

Organization functions, and Delegations

of Authority of the Department of

Health and Human Services (45 FR

67772–76, dated October 14, 1980, and

corrected at 45 FR 69296, October 20,

1980, as amended most recently at 63

FR 2256, dated January 14, 1998) is

amended to reflect the restructuring of

the Office of the Director, National

Center for Infectious Disease, Centers for

Disease Control and Prevention. The

functional statement for the Office of the

Director is being revised accordingly.

Section C–B, Organization and

Functions, is hereby amended as

follows:

Delete the functional statement for the

Office of the Director (CR1) and insert

the following:

(1) Directs and manages the programs

and activities of the National Center for

Infectious Diseases (NCID); (2) provides

leadership for the implementation of the

Emerging Infections Plan to enhance the

prevention and control of infectious

diseases nationally and internationally;

(3) provides leadership and guidance on

policy, program planning and

development, program management,

and operations; (4) provides NCID-wide

administrative and program services,

and coordinates or assures coordination

with the appropriate CDC staff offices

on administrative and program matters;

(5) provides liaison with other

Governmental agencies, international

organizations, including the World

Health Organization, and other outside

groups; (6) coordinates, in collaboration

with the appropriate NCID and CDC

components, international health

activities relating to the prevention and

control of infectious diseases; (7)

advises the Director, CDC, on policy

matters concerning NCID programs and

activities; (8) coordinates development

and review of regulatory documents and

congressional reports; (9) analyzes

health programs and proposed

legislation with respect to NCID’s

programs, goals and objectives; (10)

provides leadership and support for

NCID Programs in the areas of statistics,

information technology, and database

management.

Delete the title and functional

statement for the Office of Planning and